| Title : The Application of [(68)Ga]-Labeled FAPI-04 PET\/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient-Derived Orthotopic Xenograft Models - Zhang_2022_Contrast.Media.Mol.Imaging_2022_6596702 |
| Author(s) : Zhang H , An J , Wu P , Zhang C , Zhao Y , Tan D , Shi C , Ge X |
| Ref : Contrast Media Mol Imaging , 2022 :6596702 , 2022 |
|
Abstract :
[(18)F]FDG as a probe of PET/CT is a radiolabeled glucose analogue taken up by most cells, but its batch activity is limited. [(68)Ga]FAPI-04 is a promising alternative based on a fibroblast activation protein-specific inhibitor (FAPI) labeled with radiotracer FAP. Here, a series of databases suggested that FAP expression was significantly different in pancreatic cancer compared to normal tissue. The FAP-positive fibroblasts were evaluated around the tumor cells and the stroma. A patient-derived orthotopic xenograft (PDOX) model of pancreatic adenocarcinoma (PDAC) exhibits significantly higher quantitative uptake of [(68)Ga]FAPI-04 (P < 0.05) than [(18)F]FDG PET/CT in various organs. Because of relatively high (T/M) ratios, the [68Ga]FAPI-04 is excellent for B-mode ultrasound, NIRF, and PET/CT. Thus, [(68)Ga]FAPI-04 PET displayed a better tumor specificity and can be a potential application for the early detection of pancreatic cancer. |
| PubMedSearch : Zhang_2022_Contrast.Media.Mol.Imaging_2022_6596702 |
| PubMedID: 36051919 |
| Inhibitor | FAPI-04 |
Zhang H, An J, Wu P, Zhang C, Zhao Y, Tan D, Shi C, Ge X (2022)
The Application of [(68)Ga]-Labeled FAPI-04 PET\/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient-Derived Orthotopic Xenograft Models
Contrast Media Mol Imaging
2022 :6596702
Zhang H, An J, Wu P, Zhang C, Zhao Y, Tan D, Shi C, Ge X (2022)
Contrast Media Mol Imaging
2022 :6596702